Overview

• HHS Secretary Robert F. Kennedy Jr. told senators the prior administration "twisted" mifepristone safety data, citing an 11% safety signal he says was buried.
• He said he spoke with FDA Commissioner Marty Makary and that the agency’s review is ongoing with new data being evaluated, though no timeline was provided.
• Kennedy indicated access rules could be revisited, including Biden-era changes that expanded telemedicine dispensing and prescriber eligibility.
• The push follows an April analysis from the Ethics and Public Policy Center alleging about 10.93% serious complications within 45 days of use.
• Medical experts have challenged that analysis as flawed and not peer-reviewed, noting misclassification issues such as counting ectopic pregnancies as pill complications.